Scholarlink

<p>Cardiovascular drug therapy in adults is steadily progressing. However, the extent to which children with heart disease in Switzerland benefit from this progress remains unknown. This survey aimed to investigate the current outpatient prescribing practices among paediatric cardiologists in Switzerland.&#xa0;We conducted a cross-sectional survey among Swiss paediatric cardiologists. The physicians were asked to state how often they administer drugs on a pre-defined list for the following indications: heart failure, arrhythmia and thromboembolism.&#xa0;Forty-three (56%) out of 77 eligible physicians completed the survey. For paediatric heart failure, the three most frequently prescribed drugs were hydrochlorothiazide (‘often prescribed’ by <i>n</i> = 25, 58%), lisinopril (<i>n</i> = 24, 56%), and spironolactone (<i>n</i> = 32, 74%). The most frequently prescribed drugs for arrhythmia and thromboembolism were propranolol (<i>n</i> = 26, 60%) and acetylsalicylic acid (<i>n</i> = 31, 72%), respectively. Newer drugs such as sacubitril/valsartan (‘never prescribed’ by <i>n</i> = 20, 47%), sodium-glucose cotransporter type 2 inhibitors (<i>n</i> = 40, 93%), and direct oral anticoagulants (<i>n</i> = 20, 47%) were rarely used.</p><p><i>Conclusion:</i>&#xa0;The drugs used to treat heart failure, arrhythmia, and thromboembolism in Switzerland largely reflect current international recommendations. Nevertheless, novel drugs are rarely used. In addition to the lack of large randomized controlled drug trials in children, important obstacles are lack of authorization, lack of reimbursement, and lack of suitable formulations. These issues should be addressed by both the industry and healthcare providers to continuously improve drug therapy for children with heart disease.<Table Float="No" ID="Taba"> <tgroup cols="2"> <colspec align="left" colname="c1" colnum="1" /> <colspec align="left" colname="c2" colnum="2" /> <tbody> <row> <entry nameend="c2" namest="c1"> <p><b>What is Known:</b></p> <p>• <i>Evidence for drug use in Paediatric cardiology mostly relies on extrapolation from adult studies and pathophysiological considerations</i>.</p> <p>• <i>Drug choices are also influenced by drug approval, insurance reimbursement, and availability of age-appropriate formulations</i>.</p> </entry> </row> <row> <entry nameend="c2" namest="c1"> <p><b>What is New:</b></p> <p>• <i>Swiss paediatric cardiologists predominantly rely on established drugs to treat cardiovascular diseases in children, with the use of newer drugs remaining limited</i>.</p> <p>• <i>On top of expert consensus, adult evidence, and drug availability, drug prescription appears to be strongly influenced by the availability of child-friendly formulations</i>.</p> </entry> </row> </tbody> </tgroup> </Table></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Outpatient drug therapy for children with heart disease in Switzerland: a survey

  • 期刊论文

  • 发表日期：

    2026年5月7日

查看全文
  • Joel Bärlocher,
  • Angela Caduff Good,
  • Stefano Di Bernardo,
  • Sebastiano A. G. Lava,
  • Dominik Stambach,
  • Cécile Tissot,
  • Walter Knirsch,
  • Julie Wacker,
  • Anna Cavigelli-Brunner,
  • Alessandra Bosch,
  • Christian Balmer

摘要

Cardiovascular drug therapy in adults is steadily progressing. However, the extent to which children with heart disease in Switzerland benefit from this progress remains unknown. This survey aimed to investigate the current outpatient prescribing practices among paediatric cardiologists in Switzerland. We conducted a cross-sectional survey among Swiss paediatric cardiologists. The physicians were asked to state how often they administer drugs on a pre-defined list for the following indications: heart failure, arrhythmia and thromboembolism. Forty-three (56%) out of 77 eligible physicians completed the survey. For paediatric heart failure, the three most frequently prescribed drugs were hydrochlorothiazide (‘often prescribed’ by n = 25, 58%), lisinopril (n = 24, 56%), and spironolactone (n = 32, 74%). The most frequently prescribed drugs for arrhythmia and thromboembolism were propranolol (n = 26, 60%) and acetylsalicylic acid (n = 31, 72%), respectively. Newer drugs such as sacubitril/valsartan (‘never prescribed’ by n = 20, 47%), sodium-glucose cotransporter type 2 inhibitors (n = 40, 93%), and direct oral anticoagulants (n = 20, 47%) were rarely used.

Conclusion: The drugs used to treat heart failure, arrhythmia, and thromboembolism in Switzerland largely reflect current international recommendations. Nevertheless, novel drugs are rarely used. In addition to the lack of large randomized controlled drug trials in children, important obstacles are lack of authorization, lack of reimbursement, and lack of suitable formulations. These issues should be addressed by both the industry and healthcare providers to continuously improve drug therapy for children with heart disease.

What is Known:

• Evidence for drug use in Paediatric cardiology mostly relies on extrapolation from adult studies and pathophysiological considerations.

• Drug choices are also influenced by drug approval, insurance reimbursement, and availability of age-appropriate formulations.

What is New:

• Swiss paediatric cardiologists predominantly rely on established drugs to treat cardiovascular diseases in children, with the use of newer drugs remaining limited.

• On top of expert consensus, adult evidence, and drug availability, drug prescription appears to be strongly influenced by the availability of child-friendly formulations.